These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24469836)

  • 41. TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFκB.
    Hénaut L; Sanz AB; Martin-Sanchez D; Carrasco S; Villa-Bellosta R; Aldamiz-Echevarria G; Massy ZA; Sanchez-Nino MD; Ortiz A
    Cell Death Dis; 2016 Jul; 7(7):e2305. PubMed ID: 27441657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
    Zhou H; Ekmekcioglu S; Marks JW; Mohamedali KA; Asrani K; Phillips KK; Brown SA; Cheng E; Weiss MB; Hittelman WN; Tran NL; Yagita H; Winkles JA; Rosenblum MG
    J Invest Dermatol; 2013 Apr; 133(4):1052-62. PubMed ID: 23190886
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TWEAK/Fn14 activation induces keratinocyte proliferation under psoriatic inflammation.
    Cheng H; Xu M; Liu X; Zou X; Zhan N; Xia Y
    Exp Dermatol; 2016 Jan; 25(1):32-7. PubMed ID: 26264384
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor Necrosis Factor Receptor Mediates Fibroblast Growth Factor-Inducible 14 Signaling.
    Wang X; Xiao S; Xia Y
    Cell Physiol Biochem; 2017; 43(2):579-588. PubMed ID: 28934756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression.
    Bharadwaj U; Marin-Muller C; Li M; Chen C; Yao Q
    Mol Cancer; 2011 Aug; 10():106. PubMed ID: 21880146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibroblast growth factor-inducible 14 mediates macrophage infiltration in heart to promote pressure overload-induced cardiac dysfunction.
    Unudurthi SD; Nassal DM; Patel NJ; Thomas E; Yu J; Pierson CG; Bansal SS; Mohler PJ; Hund TJ
    Life Sci; 2020 Apr; 247():117440. PubMed ID: 32070706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Specific Targeting of Antiapoptotic Bcl-2 Proteins as a Radiosensitizing Approach in Solid Tumors.
    Sobol B; Azzam Nieto O; Eberlein EL; Scherr AL; Ismail L; Kessler A; Nader L; Schwab M; Hoffmeister P; Schmitt N; Jäger D; Welte S; Seidensaal K; Christopoulos P; Heilig C; Kriegsmann K; Fröhling S; Kriegsmann M; Hess J; Köhler BC
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention.
    Gu L; Dai L; Cao C; Zhu J; Ding C; Xu HB; Qiu L; Di W
    PLoS One; 2013; 8(3):e57436. PubMed ID: 23469193
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration.
    Lee MW; Kim DS; Lee JH; Lee BS; Lee SH; Jung HL; Sung KW; Kim HT; Yoo KH; Koo HH
    Cancer Sci; 2011 Oct; 102(10):1822-8. PubMed ID: 21722267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis.
    Morosetti R; Gliubizzi C; Sancricca C; Broccolini A; Gidaro T; Lucchini M; Mirabella M
    Am J Pathol; 2012 Apr; 180(4):1603-13. PubMed ID: 22314077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TWEAK signals through JAK-STAT to induce tumor cell apoptosis.
    Chapman MS; Wu L; Amatucci A; Ho SN; Michaelson JS
    Cytokine; 2013 Jan; 61(1):210-7. PubMed ID: 23107828
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Critical contribution of MCL-1 in EMT-associated chemo-resistance in A549 non-small cell lung cancer.
    Toge M; Yokoyama S; Kato S; Sakurai H; Senda K; Doki Y; Hayakawa Y; Yoshimura N; Saiki I
    Int J Oncol; 2015 Apr; 46(4):1844-8. PubMed ID: 25647738
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TWEAK/Fn14 axis in respiratory diseases.
    Wang M; Xie Z; Xu J; Feng Z
    Clin Chim Acta; 2020 Oct; 509():139-148. PubMed ID: 32526219
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities.
    Burkly LC
    Semin Immunol; 2014 Jun; 26(3):229-36. PubMed ID: 24636536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system.
    Echeverry R; Wu F; Haile WB; Wu J; Yepes M
    J Neuroinflammation; 2012 Mar; 9():45. PubMed ID: 22394384
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).
    Fick A; Lang I; Schäfer V; Seher A; Trebing J; Weisenberger D; Wajant H
    J Biol Chem; 2012 Jan; 287(1):484-495. PubMed ID: 22081603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation.
    Brown SA; Richards CM; Hanscom HN; Feng SL; Winkles JA
    Biochem J; 2003 Apr; 371(Pt 2):395-403. PubMed ID: 12529173
    [TBL] [Abstract][Full Text] [Related]  

  • 59. miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma.
    Xu RD; Feng F; Yu XS; Liu ZD; Lao LF
    Int J Immunopathol Pharmacol; 2018; 32():2058738418786656. PubMed ID: 30014744
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.
    Peddaboina C; Jupiter D; Fletcher S; Yap JL; Rai A; Tobin RP; Jiang W; Rascoe P; Rogers MK; Smythe WR; Cao X
    BMC Cancer; 2012 Nov; 12():541. PubMed ID: 23171055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.